Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Novel NPM1 mutation in the 3'-untranslated region identified in two patients with acute myeloid leukemia.

Abraham A, Karathedath S, Kumaraswamy V, Jayavelu AK, Mani S, Srivastava VM, Zhang W, Zhou T, George B, Srivastava A, Mathews V, Balasubramanian P.

Leuk Lymphoma. 2014 Jun;55(6):1421-4. doi: 10.3109/10428194.2013.838235. Epub 2013 Oct 9. No abstract available.

PMID:
23998253
2.

A polymorphism in the 3'-untranslated region of the NPM1 gene causes illegitimate regulation by microRNA-337-5p and correlates with adverse outcome in acute myeloid leukemia.

Cheng CK, Kwan TK, Cheung CY, Ng K, Liang P, Cheng SH, Chan NP, Ip RK, Wong RS, Lee V, Li CK, Yip SF, Ng MH.

Haematologica. 2013 Jun;98(6):913-7. doi: 10.3324/haematol.2012.073015. Epub 2012 Oct 12.

3.

Nucleophosmin mutation in Southeast Asian acute myeloid leukemia: eight novel variants, FLT3 coexistence and prognostic impact of NPM1/FLT3 mutations.

Boonthimat C, Thongnoppakhun W, Auewarakul CU.

Haematologica. 2008 Oct;93(10):1565-9. doi: 10.3324/haematol.12937. Epub 2008 Jul 18.

4.

NPM1 gene mutation in Egyptian patients with cytogenetically normal acute myeloid leukemia.

Sofan MA, Elmasry S, Salem DA, Bazid MM.

Clin Lab. 2014;60(11):1813-22.

PMID:
25648021
5.

Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing.

Salipante SJ, Fromm JR, Shendure J, Wood BL, Wu D.

Mod Pathol. 2014 Nov;27(11):1438-46. doi: 10.1038/modpathol.2014.57. Epub 2014 Apr 18.

6.

Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.

Krönke J, Schlenk RF, Jensen KO, Tschürtz F, Corbacioglu A, Gaidzik VI, Paschka P, Onken S, Eiwen K, Habdank M, Späth D, Lübbert M, Wattad M, Kindler T, Salih HR, Held G, Nachbaur D, von Lilienfeld-Toal M, Germing U, Haase D, Mergenthaler HG, Krauter J, Ganser A, Göhring G, Schlegelberger B, Döhner H, Döhner K.

J Clin Oncol. 2011 Jul 1;29(19):2709-16. doi: 10.1200/JCO.2011.35.0371. Epub 2011 May 9.

PMID:
21555683
7.

CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.

Dang H, Chen Y, Kamel-Reid S, Brandwein J, Chang H.

Hum Pathol. 2013 Oct;44(10):2038-46. doi: 10.1016/j.humpath.2013.03.007. Epub 2013 May 21.

PMID:
23701943
8.

[C-kit, NPM1 and FLT3 gene mutation patterns and their prognostic significance in 656 Chinese patients with acute myeloid leukemia].

Ding ZX, Shen HJ, Miao JC, Chen SN, Qiu QC, Qi XF, Jin ZM, Wu DP, He J.

Zhonghua Xue Ye Xue Za Zhi. 2012 Oct;33(10):829-34. Chinese.

PMID:
23384905
9.

Novel mutations of the nucleophosmin (NPM-1) gene in Egyptian patients with acute myeloid leukemia: a pilot study.

Kassem N, Hamid AA, Attia T, Baathallah S, Mahmoud S, Moemen E, Safwat E, Khalaf M, Shaker O.

J Egypt Natl Canc Inst. 2011 Jun;23(2):73-8. doi: 10.1016/j.jnci.2011.09.003. Epub 2011 Oct 13. Erratum in: J Egypt Natl Canc Inst. 2012 Jun;24(2):105.

10.

Cytoplasmic expression of nucleophosmin accurately predicts mutation in the nucleophosmin gene in patients with acute myeloid leukemia and normal karyotype.

Luo J, Qi C, Xu W, Kamel-Reid S, Brandwein J, Chang H.

Am J Clin Pathol. 2010 Jan;133(1):34-40. doi: 10.1309/AJCPCI1FFE2DRXIV.

PMID:
20023256
11.

Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations.

Guenounou S, Delabesse E, Récher C.

Eur J Haematol. 2014 Dec;93(6):533-6. doi: 10.1111/ejh.12334. Epub 2014 Apr 18.

PMID:
24689895
12.

"Cup-like" blasts in acute myeloid leukemia with FLT3 and NPM1 mutations.

Vidholia A, Menon MP.

Blood. 2015 Jan 29;125(5):889. No abstract available.

13.

Lack of nucleophosmin mutation in patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.

Shiseki M, Kitagawa Y, Wang YH, Yoshinaga K, Kondo T, Kuroiwa H, Okada M, Mori N, Motoji T.

Leuk Lymphoma. 2007 Nov;48(11):2141-4.

PMID:
17990177
14.

Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse.

Sockel K, Wermke M, Radke J, Kiani A, Schaich M, Bornhäuser M, Ehninger G, Thiede C, Platzbecker U.

Haematologica. 2011 Oct;96(10):1568-70. doi: 10.3324/haematol.2011.044388. Epub 2011 Jul 12. No abstract available.

15.

Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations.

Dvorakova D, Racil Z, Jeziskova I, Palasek I, Protivankova M, Lengerova M, Razga F, Mayer J.

Am J Hematol. 2010 Dec;85(12):926-9. doi: 10.1002/ajh.21879.

16.

Reply to "rare coincident NPM1 and RUNX1 mutations in intermediate risk acute myeloid leukemia display similar patterns to single mutated cases". Haematologica 2014;99(2):e20-21.

Mendler JH, Marcucci G, Bloomfield CD.

Haematologica. 2014 Feb;99(2):e22. doi: 10.3324/haematol.2013.100669. No abstract available.

17.

Characterization of acute myeloid leukemia with PTPN11 mutation: the mutation is closely associated with NPM1 mutation but inversely related to FLT3/ITD.

Hou HA, Chou WC, Lin LI, Chen CY, Tang JL, Tseng MH, Huang CF, Chiou RJ, Lee FY, Liu MC, Tien HF.

Leukemia. 2008 May;22(5):1075-8. Epub 2007 Nov 1. No abstract available.

PMID:
17972951
18.

Molecular and alternative methods for diagnosis of acute myeloid leukemia with mutated NPM1: flexibility may help.

Falini B, Martelli MP, Pileri SA, Mecucci C.

Haematologica. 2010 Apr;95(4):529-34. doi: 10.3324/haematol.2009.017822. No abstract available.

19.

NPM1 for MRD? Droplet Like It's Hot!

Wertheim GBW, Bagg A.

J Mol Diagn. 2017 Jul;19(4):498-501. doi: 10.1016/j.jmoldx.2017.04.008.

PMID:
28645444
20.

An allele-specific rt-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia.

Ottone T, Ammatuna E, Lavorgna S, Noguera NI, Buccisano F, Venditti A, Giannì L, Postorino M, Federici G, Amadori S, Lo-Coco F.

J Mol Diagn. 2008 May;10(3):212-6. doi: 10.2353/jmoldx.2008.070166. Epub 2008 Apr 10.

Supplemental Content

Support Center